Grant Number:	5R01CA142714-08 Interpret this number
Primary Investigator:	Poynter, Jenny
Organization:	University Of Minnesota
Project Title:	Predictors of Myelodysplastic Syndrome in Minnesota
Fiscal Year:	2020

Abstract Myelodysplastic syndromes (MDS) are part of a heterogeneous and overlapping group of clonal diseases that arise in the hematopoietic stem or progenitor cells and also include acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), and the hybrid MDS/MPN entities. Individuals with MDS have a high risk of progressing to leukemia, with approximately 30% expected to develop AML. Outcomes for MDS are poor, with 5 year relative survival estimates below 50%, suggesting that early detection and prevention could have a large impact. During our initial funding period, we conducted the first population-based case control study of MDS, including recruitment of over 550 cases. In this competing renewal application, we propose to capitalize on our well-characterized study population to investigate the contribution of genetic variation to MDS risk and to evaluate the role of the killer cell immunoglobulin receptors (KIR) on incidence and survival. Our specific aims are to: 1) Identify germline susceptibility variants for MDS through collaboration with the MDS Clinical Research Consortium; 2) Evaluate the relationship between KIR haplotypes and risk of MDS; and 3) Understand the role of KIR gene haplotypes in disease progression and survival, overall and by MDS subtype. We hypothesize that we will identify variants that predict MDS risk and that risk estimates will be larger in cases with high risk MDS subtypes who are more likely to progress to AML. We further hypothesize that KIR haplotype B will be identified at a lower frequency in MDS cases compared with population controls and that KIR haplotype A will be associated with worse prognosis. We will genotype germline DNA samples from 465 MDS cases from our case-control study, 200 MDS cases from Moffitt Cancer Center and 1,119 age- matched population controls using the Illumina HumanOmni2.5 array. We will use available genotyping data from 1,700 MDS cases from the MDS Clinical Research Consortium and 4,597 healthy controls for replication and meta-analysis. In order to improve our power to detect associations, we will restrict our analysis to regions of open chromatin in myeloid cells as determined by ATAC-seq of primary cell cultures. For Aim 2, targeted capture and sequencing will be used to measure variation in the 143kb region containing the KIR genes on chromosome 19 (position 5537984-55378670). We will compare the two main KIR gene haplotype blocks (A and B) in cases and controls. To evaluate the impact of KIR haplotypes on progression, we will treat the 457 confirmed MDS cases as a cohort and evaluate associations between KIR haplotype and progression to AML and survival. The role of common genetic variation is largely unexplored in MDS; however, the few studies that have been conducted provide a rationale for further evaluation. Identifying predictors of rapid death from MDS, such as KIR haplotypes or alleles, could provide clues to the underlying biology in this subgroup and suggest new avenues for therapy. Adoptive NK cell therapy is one such option that is already in development for treatment of hematologic malignancy.




Predicted leukocyte telomere length and risk of myeloid neoplasms.
Authors: Sullivan S.M. , Cole B. , Lane J. , Meredith J.J. , Langer E. , Hooten A.J. , Roesler M. , McGraw K.L. , Pankratz N. , Poynter J.N. .
Source: Human molecular genetics, 2023-10-04; 32(20), p. 2996-3005.
PMID: 37531260
Related Citations

Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes.
Authors: Linabery A.M. , Roesler M.A. , Richardson M. , Warlick E.D. , Nguyen P.L. , Cioc A.M. , Poynter J.N. .
Source: Cancer epidemiology, 2022 Feb; 76, p. 102090.
EPub date: 2022-01-05.
PMID: 34995873
Related Citations

The association between non-steroidal anti-inflammatory drugs (NSAIDs) and myelodysplastic syndromes in the Adults in Minnesota with Myelodysplastic Syndromes (AIMMS) Study.
Authors: Hubbard A.K. , Richardson M. , Rosesler M.A. , Cioc A. , Nguyen P.L. , Warlick E. , Poynter J.N. .
Source: Leukemia & lymphoma, 2021 Jun; 62(6), p. 1474-1481.
EPub date: 2021-01-08.
PMID: 33416407
Related Citations

Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS).
Authors: Yarosh R. , Roesler M.A. , Murray T. , Cioc A. , Hirsch B. , Nguyen P. , Warlick E. , Poynter J.N. .
Source: Cancer causes & control : CCC, 2021 Mar; 32(3), p. 241-250.
EPub date: 2021-01-04.
PMID: 33392905
Related Citations

Alcohol use is not a significant contributor to myelodysplastic syndromes.
Authors: Duffy E.A. , Nguyen P.L. , Cioc A. , Warlick E. , Roesler M.A. , Poynter J.N. .
Source: Cancer causes & control : CCC, 2020 Jun; 31(6), p. 549-557.
EPub date: 2020-04-13.
PMID: 32285234
Related Citations

Factors predicting early mortality after new diagnosis of myelodysplastic syndrome: A population-based study.
Authors: Jacobsen A.M. , Poynter J.N. , Richardson M.R. , Nguyen P.L. , Hirsch B. , Cioc A. , Roesler M.A. , Warlick E.D. .
Source: European journal of haematology, 2019 Jul; 103(1), p. 56-63.
EPub date: 2019-05-16.
PMID: 31058390
Related Citations

Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study.
Authors: Poynter J.N. , Richardson M. , Roesler M. , Blair C.K. , Hirsch B. , Nguyen P. , Cioc A. , Cerhan J.R. , Warlick E. .
Source: International journal of cancer, 2017-01-01; 140(1), p. 23-33.
EPub date: 2016-09-24.
PMID: 27603749
Related Citations

Association between mitochondrial DNA haplogroup and myelodysplastic syndromes.
Authors: Poynter J.N. , Richardson M. , Langer E. , Hooten A.J. , Roesler M. , Hirsch B. , Nguyen P.L. , Cioc A. , Warlick E. , Ross J.A. .
Source: Genes, chromosomes & cancer, 2016 Sep; 55(9), p. 688-93.
EPub date: 2016-06-21.
PMID: 27121678
Related Citations

Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes.
Authors: Poynter J.N. , Richardson M. , Blair C.K. , Roesler M.A. , Hirsch B.A. , Nguyen P. , Cioc A. , Warlick E. , Cerhan J.R. , Ross J.A. .
Source: Cancer epidemiology, 2016 Feb; 40, p. 134-40.
EPub date: 2015-12-22.
PMID: 26720913
Related Citations

Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota.
Authors: Smith A.R. , Warlick E.D. , Roesler M.A. , Poynter J.N. , Richardson M. , Nguyen P. , Cioc A. , Hirsch B. , Ross J.A. .
Source: Annals of hematology, 2015 Oct; 94(10), p. 1667-75.
EPub date: 2015-06-11.
PMID: 26063191
Related Citations

Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients.
Authors: Pease D.F. , Ross J.A. , Poynter J.N. , Nguyen P.L. , Hirsch B. , Cioc A. , Roesler M.A. , Warlick E.D. .
Source: Cancer epidemiology, 2015 Apr; 39(2), p. 222-8.
EPub date: 2015-02-18.
PMID: 25701277
Related Citations

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Authors: Gleason M.K. , Ross J.A. , Warlick E.D. , Lund T.C. , Verneris M.R. , Wiernik A. , Spellman S. , Haagenson M.D. , Lenvik A.J. , Litzow M.R. , et al. .
Source: Blood, 2014-05-08; 123(19), p. 3016-26.
EPub date: 2014-03-20.
PMID: 24652987
Related Citations

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Authors: Wiernik A. , Foley B. , Zhang B. , Verneris M.R. , Warlick E. , Gleason M.K. , Ross J.A. , Luo X. , Weisdorf D.J. , Walcheck B. , et al. .
Source: Clinical cancer research : an official journal of the American Association for Cancer Research, 2013-07-15; 19(14), p. 3844-55.
EPub date: 2013-05-20.
PMID: 23690482
Related Citations